Lenoss Medical raises $4M financing for spine allograft

Biologics

Lenoss Medical closed an oversubscribed series A funding round of $4 million to help accelerate commercialization of its OsteoPearl spinal allograft. 

The OsteoPearl biologic allograft is made from 100% cortical bone and is designed to stabilize vertebral compression fractures, according to a May 9 news release. The investment will also expand clinical evidence and support development.

Xcellerant Ventures, Highpoint Ventures, Vodia Capital, RightHill Ventures and other groups were involved with funding.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like

Thank you so much for your interest in our content. Please register to access this complimentary archived content. By registering, you will receive our newsletter which can be opted out of at any time.

 

 

Already Registered? Click here to confirm.